#USA #San Diego #Illumina #StrataMap #Spatial Solution

Illumina Unveils StrataMap Spatial Solution

In a significant advancement in the field of spatial biology, Illumina, Inc. has today announced the introduction of the StrataMap Spatial Solution. This new product is poised to revolutionize transcriptomics research by providing researchers with unparalleled coverage and resolution, enabling a more profound understanding of tissue architecture and function.

Unmatched Capabilities for Researchers

The StrataMap Spatial Solution is designed as an end-to-end research tool that delivers insights into spatial transcriptomics, a method crucial to various areas of biological science such as developmental biology, oncology, and neuroscience. As researchers seek to unravel the complexities of tissue structures and functions, StrataMap Spatial offers groundbreaking capabilities: it achieves true single-cell resolution with unbiased whole-transcriptome profiling.

Dr. Steve Barnard, Chief Technology Officer at Illumina, emphasizes the transformative nature of this tool. He notes, "Spatial biology provides a fresh perspective on how genetic coding is expressed in our bodies." The significance of this innovation cannot be overstated, as it has already shown promise in mapping intricate tissues and tracking tumor development in live samples, furthering the pursuit of precision medicine.

Features That Stand Out

What sets StrataMap Spatial apart is its combination of features that include:

• - Large Capture Area: The solution offers a flexible 7.5 cm² capture area suitable for simultaneously profiling multiple fresh-frozen tissue sections of various sizes, enabling the creation of multi-dimensional tissue maps.
• - High Throughput: Capable of processing over 2,000 samples per year, StrataMap Spatial is engineered for scalability, meeting the demands of both research and biopharmaceutical markets.
• - Swift Turnaround: With sequencing processes that can be completed in as little as 22 hours, including imaging and analysis, Illumina ensures researchers can transition from raw samples to actionable insights quickly, often within a five-day timeframe.
• - Integration with Existing Workflows: Illumina recognizes the need for accessibility; therefore, the StrataMap Spatial Solution integrates effortlessly into existing histopathology workflows using widely available platforms like NovaSeq and NextSeq.

Comprehensive Analysis with Advanced Software

Alongside its hardware capabilities, StrataMap Spatial is complemented by sophisticated bioinformatics packages that streamline the process from imaging to analysis. Tools such as DRAGEN and Illumina Connected Multiomics allow for efficient processing of large spatial datasets while preserving the depth and resolution achieved.

With machine-learning-driven processes, researchers can automate cell segmentation and transcript assignment, equipping them with powerful tools for spatial exploration and biological interpretation that merge transcriptomic with genomic and epigenetic data.

Real-World Applications in Research

In initial trials, teams from Beth Israel Deaconess Medical Center (BIDMC) and Cancer Research UK have begun utilizing StrataMap Spatial to tackle complex research challenges.

For instance, BIDMC researchers successfully mapped intricate lymphatic tissues, producing the first whole transcriptome datasets for human lymphatic collector vessels. Dr. Ioannis Vlachos highlighted the efficacy of the StrataMap’s large capture area, which facilitated the reconstruction of elaborate 3D models reflective of these challenging samples.

Meanwhile, the Cancer Research UK team aims to characterize the tumor microenvironments of glioma and glioblastoma cancers to enhance surgical precision and personalize treatment strategies. As Dr. Ania Piskorz remarked, this capability transcends previous limitations in studying large tissue samples and will significantly inform future therapeutic responses.

Conclusion

With the launch of the StrataMap Spatial Solution, Illumina continues to establish itself at the forefront of genomic innovation and research efficacy. Researchers interested in enhancing their studies with this tool can learn more about its capabilities and order it directly starting this month. The potential for advancing our understanding of complex biological systems and improving healthcare outcomes is substantial with this newly introduced spatial solution.

For more insights and live demonstrations, attendees can visit Illumina’s booth at the European Association for Cancer Research (EACR) meeting occurring from June 8 to 11.

About Illumina

Known for pioneering advancements in DNA sequencing and array-based technologies, Illumina is committed to improving human health by unlocking the codes of the genome. This latest innovation highlights their ongoing dedication to helping researchers and clinicians in their quest for deeper biological insights and more effective therapies.